Increased risk of ovarian hyperstimulation syndrome following controlled ovarian hyperstimulation in patients with vascular endothelial growth factor +405 cc genotype

Gynecological Endocrinology

Volumn 28, Issue 11, 2012, Pages 845-849

  Hanevik, Hans Ivar ^a   Hilmarsen, Hilde Tveitan ^b   Skjelbred, Camilla Furu ^b   Tanbo, Tom ^c   Kahn, Jarl A ^a  

^a Telemark Hospital   (Norway)

^b TELEMARK HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

FSH; IVF; Ovarian response; Polymorphisms; VEGF

Indexed keywords

CHORIONIC GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; NAFARELIN; NAFARELIN ACETATE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CONTROLLED OVARY HYPERSTIMULATION; CONTROLLED STUDY; FEMALE; FERTILIZATION IN VITRO; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MALE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84867531223     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.683056     Document Type: Article

References (27)

1. Rizk B, Aboulghar MA. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden PR, editor. A textbook of in vitro fertilization and assisted reproduction: The Bourne Hall guide to clinical and laboratory practice. 2nd ed. Lancs./New York: The Parthenon Publishing Group; 1999. pp 131-155.
2. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, Connolly DT, Robertson DM. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-236.
3. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611.
4. Pau E, Alonso-Muriel I, Gez R, Novella E, Ruiz A, Garc-Velasco JA, Sim; C, Pellicer A. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod 2006; 21:1453-1460.
5. Enskog A, Nilsson L, Brnstr M. Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): Results of a prospective cohort study with matched controls. Eur J Obstet Gynecol Reprod Biol 2001;96:196-201.
6. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production. Cytokine 2000;12:1232-1235.
7. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635-1639.
8. Steffensen KD, Waldstr M, Brandslund I, Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010;117:109-116.
9. Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, et al. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 2007;50:760-767.
10. Kariyazono H, Ohno T, Khajoee V, Ihara K, Kusuhara K, Kinukawa N, Mizuno Y, Hara T. Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res 2004;56:953-959.
11. Simoni M, Tempfer CB, Destenaves B, Fauser BC. Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response. Hum Reprod Update 2008;14:459-484.
12. Popovic-Todorovic B, Loft A, Lindhard A, Bangsbl S, Andersson AM, Andersen AN. A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 2003;18:781-787.
13. Enskog A, Henriksson M, Unander M, Nilsson L, Brnstr M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71:808-814.
14. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res 2005;15:1592-1593.
15. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res 2001;29:308-311.
16. Gentilini D, Somigliana E, Vigano P, Vignali M, Busacca M, Di Blasio AM. The vascular endothelial growth factor +405G>C polymorphism in endometriosis. Hum Reprod 2008;23:211-215.
17. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
18. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990; 11:116-128.
19. Bhanoori M, Arvind Babu K, Pavankumar Reddy NG, Lakshmi Rao K, Zondervan K, Deenadayal M, Kennedy S, Shivaji S. The vascular endothelial growth factor (VEGF) +405G>C 5′-untranslated region polymorphism and increased risk of endometriosis in South Indian women: A case control study. Hum Reprod 2005; 20:1844-1849.
20. Byz I, SzabS, Bokodi G, Vannay A, Vhelyi B, SzabA, Tulassay T, RigJJ r. Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia. Mol Hum Reprod 2006;12:233-236.
21. Altm S, Haller K, Peters M, Hovatta O, Stavreus-Evers A, Karro H, Metspalu A, Salumets A. Allelic estrogen receptor 1 (ESR1) gene variants predict the outcome of ovarian stimulation in in vitro fertilization. Mol Hum Reprod 2007;13:521-526.
22. Hanevik HI, Hilmarsen HT, Skjelbred CF, Tanbo T, Kahn JA. Single nucleotide polymorphisms in the anti-Mlerian hormone signalling pathway do not determine high or low response to ovarian stimulation. Reprod Biomed Online 2010;21:616-623.
23. Mor; FJ, de Castro F, Royo JL, Montoro L, Mira E, Sz ME, Real LM, et al. Bone morphogenetic protein 15 (BMP15) alleles predict overresponse to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS). Pharmacogenet Genomics 2006;16:485-495.
24. Hanevik HI, Hilmarsen HT, Skjelbred CF, Tanbo T, Kahn JA. A single nucleotide polymorphism in BMP15 is associated with high response to ovarian stimulation. Reprod Biomed Online 2011;23:97-104.
25. van Disseldorp J, Franke L, Eijkemans R, Broekmans F, Macklon N, Wijmenga C, Fauser B. Genome-wide analysis shows no genomic predictors of ovarian response to stimulation by exogenous FSH for IVF. Reprod Biomed Online 2011;22:382-388.
26. KerkelE, Skottman H, Friden B, Bjuresten K, Kere J, Hovatta O. Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome. Fertil Steril 2007;87:603-606.
27. Popovic-Todorovic B, Loft A, Ziebe S, Andersen AN. Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in "standard" patients treated with 150 IU/day during the first cycle. Acta Obstet Gynecol Scand 2004;83:842-849.